Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 17/20 | 0.48 |
| ▸ | BRD7 | Q9NPI1 | 11/20 | 0.48 |
| ▸ | TAF1 | P21675 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.48 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.48 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 10/20 | 0.47 |
| ▸ | BRD2 | P25440 | 5/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.34 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575438 | 0.88 | BRD9 (0.52) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23575596 | 0.88 | BRD9 (0.49) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23575671 | 0.86 | BRD9 (0.44) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23575219 | 0.86 | BRD9 (0.51) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL21227721 | 0.84 | BRD9 (0.70) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23589992 | 0.84 | BRD9 (0.41) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23575675 | 0.82 | BRD9 (0.53) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23589965 | 0.81 | BRD9 (0.48) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23575291 | 0.78 | BRD9 (0.45) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL22291620 | 0.76 | BRD9 (0.57) | BRD9BRD7TAF1TGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | BRD9 5/4885BRD7 32/4885TAF1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.